Latest revenue
$1.0M
as of 2026-03-31
Latest net income
$-22.9M
as of 2026-03-31
Net margin
-2192.2%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Biological Products, (No Diagnostic Substances) (165 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think ALEC is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $181.0M
- Enterprise value
- $113.8M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 17.43×
- Dividend yield
- 0.0%
- 52-wk high
- $3.40
- 52-wk low
- $1.09
- Beta
- —
- Shares out
- 111.0M
5-year trend
What this company does
Item 1. Business. Overview We are a clinical-stage biotechnology company developing therapies for neurodegenerative diseases, with a focus on areas of high unmet medical need. Our work is informed by advances in disease biology, including the roles of misfolded or deficient proteins, lysosomal dysfunction, and immune and neuronal pathway disruption. Our objective is to develop product candidates that address disease through targeted mechanisms, such as removing pathogenic proteins, replacing deficient proteins, and restoring normal cellular function. We are advancing a portfolio of programs focused on genetically validated targets, supported by our expertise in drug development, protein…
AI summary unavailable — showing raw filing excerpt
Generated from ALEC's filing dated 2026-02-25
Key risks
Item 1A. Risk Factors. Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our financial statements and the related notes and the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and in our other public filings, in evaluating our business. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part…
AI summary unavailable — showing raw filing excerpt
Generated from ALEC's filing dated 2026-02-25
Profitability
Operating margin
-741.3%
414.1%Net margin
-679.2%
473.7%Return on equity
-466.3%
396.7%Return on assets
-48.7%
91.7%Leverage
Debt / equity
8.57×
218.1%Long-term debt / equity
0.30×
310.8%Debt / assets
89.5%
22.8%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $1.0M | -71.5% | $-22.9M | +43.3% | -2192.2% |
Q4 2025 2025-12-31 | $6.2M | -88.5% | $-37.3M | -1696.9% | -597.5% |
Q3 2025 2025-09-30 | $3.3M | -78.8% | $-34.7M | +17.9% | -1063.4% |
Q2 2025 2025-06-30 | $7.9M | -47.8% | $-30.5M | +21.1% | -387.7% |
Q1 2025 2025-03-31 | $3.7M | -76.9% | $-40.5M | -12.2% | -1101.6% |
Q4 2024 2024-12-31 | $54.2M | — | $-2.1M | — | -3.8% |
Q3 2024 2024-09-30 | $15.3M | +68.4% | $-42.2M | +5.1% | -275.2% |
Q2 2024 2024-06-30 | $15.1M | -73.2% | $-38.7M | -2912.8% | -256.4% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on ALEC — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$775.1K
Net activity
−$775.1K
Distinct insiders
6
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ALEC
Institutional value
$48.2M
Total shares held
26.5M
Distinct holders
62
-67 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 7.7M | $16.6M | +593.5K (+8.3%) | Added |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 3.7M | $7.9M | — | New |
| 3 | Merck & Co., Inc. | 3.5M | $7.6M | +0 (+0.0%) | No change |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.6M | $5.6M | — | New |
| 5 | DEUTSCHE BANK AG\ | 1.1M | $2.3M | +57.7K (+5.6%) | Added |
| 6 | MACKENZIE FINANCIAL CORP | 857.4K | $1.8M | +197.2K (+29.9%) | Added |
| 7 | VANGUARD FIDUCIARY TRUST CO | 577.9K | $1.2M | — | New |
| 8 | JANE STREET GROUP, LLC | 399.5K | $858.8K | -594.4K (-59.8%) | Trimmed |
| 9 | DIMENSIONAL FUND ADVISORS LP | 283.8K | $609.8K | +84.7K (+42.5%) | Added |
| 10 | Invesco Ltd. | 265.1K | $569.9K | -14.4K (-5.2%) | Trimmed |
| 11 | Bank of New York Mellon Corp | 252.3K | $542.4K | +34.4K (+15.8%) | Added |
| 12 | Nuveen, LLC | 154.9K | $333.1K | +21.7K (+16.3%) | Added |
| 13 | UBS Group AG | 145.3K | $312.5K | +25.9K (+21.7%) | Added |
| 14 | RHUMBLINE ADVISERS | 101.3K | $217.8K | -599 (-0.6%) | Trimmed |
| 15 | STRS OHIO | 86.5K | $186.0K | -23.9K (-21.6%) | Trimmed |
| 16 | Jasper Ridge Partners, L.P. | 73.5K | $158.1K | -21.5K (-22.7%) | Trimmed |
| 17 | Russell Investments Group, Ltd. | 66.1K | $142.2K | -5.8K (-8.0%) | Trimmed |
| 18 | SEI INVESTMENTS CO | 53.8K | $115.8K | +37.0K (+218.9%) | Added |
| 19 | HSBC HOLDINGS PLC | 48.5K | $104.8K | -48.5K (-50.0%) | Trimmed |
| 20 | JPMORGAN CHASE & CO | 37.4K | $75.5K | +4.8K (+14.6%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ALEC's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.